Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE10.8500
- TODAY'S CHANGE (%)-0.8400 (-7.1856%)
- Bid / Lots10.8400/ 8
- Ask / Lots10.8600/ 8
- Open / Previous Close11.7400 / 11.6900
- Day Range
- 52 Week Range
- Volume388,244
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 20364 | 11.66 |
| 09:33 ET | 1349 | 11.66 |
| 09:35 ET | 858 | 11.57 |
| 09:37 ET | 7815 | 11.38 |
| 09:39 ET | 3493 | 11.45 |
| 09:42 ET | 5687 | 11.395 |
| 09:44 ET | 2508 | 11.34 |
| 09:46 ET | 1329 | 11.36 |
| 09:48 ET | 1100 | 11.34 |
| 09:50 ET | 1390 | 11.39 |
| 09:51 ET | 500 | 11.37 |
| 09:53 ET | 4086 | 11.37 |
| 09:55 ET | 3896 | 11.375 |
| 09:57 ET | 2366 | 11.36 |
| 10:00 ET | 400 | 11.35 |
| 10:02 ET | 441 | 11.35 |
| 10:04 ET | 1130 | 11.35 |
| 10:06 ET | 2438 | 11.38 |
| 10:08 ET | 5156 | 11.39 |
| 10:09 ET | 10018 | 11.345 |
| 10:11 ET | 1015 | 11.35 |
| 10:13 ET | 1552 | 11.35 |
| 10:15 ET | 4352 | 11.355 |
| 10:18 ET | 5658 | 11.355 |
| 10:20 ET | 10589 | 11.16 |
| 10:22 ET | 1010 | 11.03 |
| 10:24 ET | 2448 | 11.125 |
| 10:26 ET | 966 | 11.1 |
| 10:27 ET | 1409 | 11.05 |
| 10:29 ET | 6484 | 11.03 |
| 10:31 ET | 4506 | 10.92 |
| 10:33 ET | 5447 | 10.93 |
| 10:36 ET | 3574 | 11.005 |
| 10:38 ET | 2100 | 10.975 |
| 10:40 ET | 758 | 10.975 |
| 10:42 ET | 856 | 10.99 |
| 10:44 ET | 550 | 10.91 |
| 10:45 ET | 4476 | 10.965 |
| 10:47 ET | 2827 | 10.965 |
| 10:49 ET | 260 | 10.965 |
| 10:51 ET | 7726 | 11.02 |
| 10:54 ET | 4094 | 11.02 |
| 10:56 ET | 6920 | 11.03 |
| 10:58 ET | 3409 | 11.03 |
| 11:00 ET | 4005 | 10.87 |
| 11:02 ET | 868 | 10.91 |
| 11:03 ET | 400 | 10.85 |
| 11:05 ET | 3672 | 10.94 |
| 11:07 ET | 908 | 10.93 |
| 11:09 ET | 1866 | 10.89 |
| 11:12 ET | 1625 | 10.83 |
| 11:14 ET | 1115 | 10.75 |
| 11:16 ET | 2658 | 10.905 |
| 11:18 ET | 100 | 10.905 |
| 11:20 ET | 983 | 10.97 |
| 11:21 ET | 100 | 10.97 |
| 11:23 ET | 7200 | 11 |
| 11:25 ET | 558 | 11.01 |
| 11:27 ET | 250 | 10.99 |
| 11:30 ET | 1326 | 10.955 |
| 11:32 ET | 467 | 10.9 |
| 11:34 ET | 715 | 10.87 |
| 11:36 ET | 262 | 10.84 |
| 11:38 ET | 1881 | 10.89 |
| 11:39 ET | 400 | 10.89 |
| 11:41 ET | 318 | 10.86 |
| 11:45 ET | 108 | 10.85 |
| 11:48 ET | 7857 | 10.8 |
| 11:50 ET | 408 | 10.8 |
| 11:52 ET | 3554 | 10.835 |
| 11:54 ET | 300 | 10.85 |
| 11:57 ET | 3777 | 10.95 |
| 11:59 ET | 11813 | 11.01 |
| 12:01 ET | 260 | 11.03 |
| 12:03 ET | 427 | 11.035 |
| 12:06 ET | 200 | 11.035 |
| 12:08 ET | 558 | 11 |
| 12:10 ET | 1872 | 10.95 |
| 12:12 ET | 1233 | 10.89 |
| 12:14 ET | 255 | 10.86 |
| 12:15 ET | 367 | 10.845 |
| 12:17 ET | 100 | 10.845 |
| 12:19 ET | 1619 | 10.87 |
| 12:21 ET | 651 | 10.87 |
| 12:24 ET | 200 | 10.865 |
| 12:26 ET | 2290 | 10.85 |
| 12:28 ET | 312 | 10.84 |
| 12:30 ET | 1744 | 10.85 |
| 12:32 ET | 1762 | 10.875 |
| 12:33 ET | 500 | 10.87 |
| 12:35 ET | 1708 | 10.9 |
| 12:37 ET | 719 | 10.91 |
| 12:39 ET | 400 | 10.96 |
| 12:42 ET | 600 | 10.965 |
| 12:44 ET | 327 | 10.97 |
| 12:46 ET | 3788 | 10.94 |
| 12:48 ET | 945 | 10.925 |
| 12:50 ET | 4653 | 10.9 |
| 12:51 ET | 1904 | 10.885 |
| 12:53 ET | 300 | 10.88 |
| 12:55 ET | 3322 | 10.88 |
| 12:57 ET | 2730 | 10.83 |
| 01:00 ET | 796 | 10.78 |
| 01:02 ET | 2496 | 10.83 |
| 01:04 ET | 7290 | 10.825 |
| 01:06 ET | 500 | 10.825 |
| 01:08 ET | 264 | 10.83 |
| 01:09 ET | 400 | 10.84 |
| 01:11 ET | 858 | 10.83 |
| 01:13 ET | 501 | 10.79 |
| 01:18 ET | 568 | 10.76 |
| 01:20 ET | 1258 | 10.81 |
| 01:22 ET | 600 | 10.8 |
| 01:24 ET | 400 | 10.79 |
| 01:26 ET | 662 | 10.74 |
| 01:27 ET | 200 | 10.78 |
| 01:29 ET | 562 | 10.775 |
| 01:31 ET | 3858 | 10.84 |
| 01:33 ET | 100 | 10.855 |
| 01:36 ET | 200 | 10.85 |
| 01:38 ET | 1184 | 10.845 |
| 01:40 ET | 505 | 10.84 |
| 01:42 ET | 517 | 10.84 |
| 01:44 ET | 828 | 10.825 |
| 01:45 ET | 499 | 10.83 |
| 01:47 ET | 1000 | 10.855 |
| 01:49 ET | 662 | 10.86 |
| 01:51 ET | 200 | 10.855 |
| 01:54 ET | 100 | 10.855 |
| 01:56 ET | 300 | 10.85 |
| 01:58 ET | 619 | 10.85 |
| 02:00 ET | 632 | 10.85 |
Nov 13, 2024
DJ Neumora Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 11:59AM ET on Wednesday Nov 13, 2024 by Dow Jones
11:59AM ET on Wednesday Nov 13, 2024 by Dow JonesDJ Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham, from 5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
5:20AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 6, 2024
Neumora Therapeutics to Participate in Upcoming Conferences in November, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 1.9B | -6.1x | --- |
Disc Medicine Inc | 1.8B | -15.0x | --- |
Viridian Therapeutics Inc | 1.7B | -4.8x | --- |
Akero Therapeutics Inc | 2.1B | -7.4x | --- |
Tarsus Pharmaceuticals Inc | 1.8B | -11.6x | --- |
Celldex Therapeutics Inc | 1.7B | -9.3x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 160.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.77 |
Book Value | $2.95 |
P/E Ratio | -6.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
